Gastrointestinal inflammation and drugs of ingredients of guanfacine hydrochloride - a phase IV clinical study of FDA data
Gastrointestinal inflammation is reported only by a few people who take drugs with ingredients of guanfacine hydrochloride. This phase IV clinical study analyzes 7,875 people who have side effects while taking drugs with ingredients of guanfacine hydrochloride from the the FDA. Among them, 5 have Gastrointestinal inflammation. Find out below who they are, when they have Gastrointestinal inflammation and more.
Drug(s) considered in the study (i.e. both brand name and generic drugs): Guanfacine hydrochloride, Intuniv, Tenex.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
7,875 people reported to have side effects when taking drugs with ingredients of guanfacine hydrochloride.
Among them, 5 people (0.06%) have Gastrointestinal inflammation
What is Gastrointestinal inflammation?
Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 816 drugs and 516 conditions by eHealthMe.
Number of reports submitted per year:
Gender of people who have Gastrointestinal inflammation when taking drugs with ingredients of guanfacine hydrochloride *:
- female: 80 %
- male: 20 %
Age of people who have Gastrointestinal inflammation when taking drugs with ingredients of guanfacine hydrochloride *:
- 0-1: 0.0 %
- 2-9: 20 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 60 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 20 %
Conditions people have *:
- Hepatitis C: 3 people, 60.00%
- Hypersensitivity: 1 person, 20.00%
- Heart Disease: 1 person, 20.00%
- Cardiac Disorder: 1 person, 20.00%
Other drugs people take *:
- Viekira Pak: 3 people, 60.00%
- Sensipar: 3 people, 60.00%
- Rocephin: 3 people, 60.00%
- Reglan: 3 people, 60.00%
- Prevacid: 3 people, 60.00%
- Norvasc: 3 people, 60.00%
- Dilaudid: 3 people, 60.00%
- Vitamin D: 2 people, 40.00%
- Zyrtec: 1 person, 20.00%
- Strattera: 1 person, 20.00%
Other side effects people have besides Gastrointestinal inflammation *:
- Enlarged Heart: 3 people, 60.00%
- Gastric Ulcer (stomach ulcer): 3 people, 60.00%
- Gastrointestinal Erosion (gradual destruction of gastrointestinal tract because of the inflamed mucous membrane lining the stomach): 3 people, 60.00%
- Upper Gastrointestinal Haemorrhage (upper gastrointestinal bleeding): 3 people, 60.00%
- Nodule (a small rock or mineral cluster): 3 people, 60.00%
- Haemorrhagic Anaemia (anaemia due to excessive bleeding): 2 people, 40.00%
- Nausea (feeling of having an urge to vomit): 2 people, 40.00%
- Faeces Discolored: 2 people, 40.00%
- Gastrointestinal Telangiectasia (permanent dilation of pre-existing small blood vessels, creating focal red lesions in gastrointestinal tract): 2 people, 40.00%
- Abdominal Discomfort: 2 people, 40.00%
* Approximation only. Some reports may have incomplete information.
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .
Drugs with ingredients of guanfacine hydrochloride, their effectiveness, alternatives and more:
How the study uses the data?
The study uses data from the FDA. It is based on guanfacine hydrochloride. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Escitalopram and Impatience - 11 seconds ago
- Zinbryta and Schizophrenia - 16 seconds ago
- Tylenol W/ Codeine and Pco2 Decreased - 18 seconds ago
- Fluorouracil and Haemodynamic Instability - 20 seconds ago
- Simponi and Nephrotic Syndrome - 23 seconds ago
- Prilosec and Accident At Home - 26 seconds ago
- Ezetimibe and Victoza drug interaction - 29 seconds ago
- Acetaminophen and Varicose Vein Ruptured - 29 seconds ago
- Atripla and Bone Disorder - 33 seconds ago
- Fluorouracil and Haemodilution - 33 seconds ago